Beijing Bohui Innovation Biotechnology Group Balance Sheet Health
Financial Health criteria checks 4/6
Beijing Bohui Innovation Biotechnology Group has a total shareholder equity of CN¥2.4B and total debt of CN¥908.3M, which brings its debt-to-equity ratio to 38.1%. Its total assets and total liabilities are CN¥4.0B and CN¥1.6B respectively. Beijing Bohui Innovation Biotechnology Group's EBIT is CN¥92.4M making its interest coverage ratio 4.1. It has cash and short-term investments of CN¥90.3M.
Key information
38.1%
Debt to equity ratio
CN¥908.27m
Debt
Interest coverage ratio | 4.1x |
Cash | CN¥90.30m |
Equity | CN¥2.38b |
Total liabilities | CN¥1.60b |
Total assets | CN¥3.98b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 300318's short term assets (CN¥1.1B) exceed its short term liabilities (CN¥1.1B).
Long Term Liabilities: 300318's short term assets (CN¥1.1B) exceed its long term liabilities (CN¥536.7M).
Debt to Equity History and Analysis
Debt Level: 300318's net debt to equity ratio (34.3%) is considered satisfactory.
Reducing Debt: 300318's debt to equity ratio has increased from 31.2% to 38.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 300318 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 300318 has less than a year of cash runway if free cash flow continues to grow at historical rates of 1.4% each year.